Amedisys (NASDAQ:AMED) Sees Unusually-High Trading Volume - Still a Buy?

Amedisys, Inc. (NASDAQ:AMED - Get Free Report) saw strong trading volume on Monday . 186,864 shares traded hands during trading, a decline of 43% from the previous session's volume of 328,166 shares.The stock last traded at $95.18 and had previously closed at $97.22.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Cantor Fitzgerald reiterated a "neutral" rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday, July 25th. William Blair cut shares of Amedisys from an "outperform" rating to a "market perform" rating in a research report on Monday, July 1st. Finally, Deutsche Bank Aktiengesellschaft cut shares of Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price target on the stock. in a research report on Monday, July 29th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $100.67.

Amedisys Trading Down 1.8 %

The firm has a market cap of $3.12 billion, a PE ratio of -149.20, a PEG ratio of 1.89 and a beta of 0.78. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. The stock's fifty day simple moving average is $97.04 and its two-hundred day simple moving average is $95.58.

Institutional Investors Weigh In On Amedisys

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Alpine Associates Management Inc. lifted its stake in shares of Amedisys by 0.9% in the second quarter. Alpine Associates Management Inc. now owns 1,280,897 shares of the health services provider's stock worth $117,586,000 after buying an additional 11,000 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Amedisys by 4.0% in the second quarter. Dimensional Fund Advisors LP now owns 514,166 shares of the health services provider's stock worth $47,202,000 after buying an additional 19,660 shares in the last quarter. Calamos Advisors LLC lifted its stake in shares of Amedisys by 11.6% in the second quarter. Calamos Advisors LLC now owns 397,347 shares of the health services provider's stock worth $36,476,000 after buying an additional 41,220 shares in the last quarter. Highbridge Capital Management LLC lifted its stake in shares of Amedisys by 34.7% in the second quarter. Highbridge Capital Management LLC now owns 323,200 shares of the health services provider's stock worth $29,670,000 after buying an additional 83,200 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in shares of Amedisys by 413.4% in the third quarter. SG Americas Securities LLC now owns 196,713 shares of the health services provider's stock worth $18,985,000 after buying an additional 158,398 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.